Search results
Found 959 matches for
The Aspirin Esomeprazole Chemoprevention Trial (AspECT) is to our knowledge one of the largest cancer prevention trials using aspirin and acid suppression in the world. In total 2557 patients with a common precancerous change in their oesophagus, called Barrett’s oesophagus, were followed up for an average of 9 years resulting in over 20,000 life-years of follow up. After informed written consent, patients were randomly allocated to four different combinations; Low acid suppression alone, High acid suppression alone, low acid suppression with 300mg aspirin and high acid suppression with 300mg aspirin. We wanted to see if we could prevent progression to local cancer/cancer in-situ (high grade dysplasia), invasive cancer or prevent death by all causes both cancer and non-cancer.
Vicki Barber
Botnar CSM OCTRU Research Delivery Research Scientists
BSc (Hons) ; FIoB; PhD Vicki Barber - OCTRU Operations Director
Andrew Carr
OCTRU Principal Investigators
MA ChM DSc FRCS FMedSci Andrew Carr - Nuffield Professor of Orthopaedics
Joanna Black
Botnar CSM OCTRU Research Delivery
BSc, PhD Joanna Black - OCTRU Head of Regulatory Affairs and Quality Assurance (HoRAQ)
Anne Francis
Botnar OCTRU Research Scientists
D.Phil Anne Francis - Clinical Trial Operational Lead – Experimental Medicine and Rheumatology
Emma Phelps
Botnar Kadoorie OCTRU Research Scientists
Emma Phelps - Postdoctoral Research Associate in Mixed Methods Research
Esther Williamson
Botnar OCTRU Research Scientists
Esther Williamson - Deputy Director, Centre for Rehabilitation Research in Oxford
Susan Wagland
Botnar Kadoorie OCTRU Research Delivery
BA, BSc, MSc, PhD Susan Wagland - Clinical Trials Manager
Emma Haines
Botnar CSM OCTRU Research Delivery
Emma Haines - OCTRU - Quality Assurance and Administration Manager